Anteris Technologies Commences American Depository Receipt Program
09 Agosto 2023 - 5:30AM
Business Wire
Anteris Technologies Ltd, (Anteris or the Company) (ASX: AVR,
OTC: ANTTY) reported today that it has established a sponsored
Level 1 American Depository Receipt (ADR) program in the United
States. The ADR program has been set up to improve U.S. investor
access to Anteris ordinary shares.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20230809932510/en/
DurAVR™ Transcatheter Heart Valve
developed by Anteris Technologies. The company has established an
American Depositary Receipt (ADR) program to improve U.S. investor
access to the company's shares. (ASX: AVR, OTC: ANTTY) (Photo:
Business Wire)
The ADRs representing Anteris ordinary shares will trade on the
over-the-counter (OTC) market. The ADR ticker symbol is
ANTTY and Deutsche Bank has been appointed as the Depositary
Bank for Anteris Technologies’ ADR program.
The Company’s ADR program does not involve the issuance of new
ordinary shares or the raising of new capital. ADRs will be
tradeable by licensed U.S. brokers in the ordinary course of
trading on the OTC market.
ADRs are a financial instrument that allow U.S. investors to
hold shares of a foreign company without the need for cross-border
or cross-currency transactions. Each ADR issued by Deutsche Bank
represents an interest in one Anteris ordinary share that has been
deposited with Deutsche Bank. ADRs are denominated in U.S.
dollars.
The program intends to simplify and streamline U.S. investors'
access to investing in Anteris by eliminating the need to deal with
foreign currencies or the complexities of trading on foreign stock
exchanges.
Anteris CEO, Wayne Paterson, said:
“Establishing an ADR program through a partnership with Deutsche
Bank will increase the Company's visibility and recognition among
U.S. investors, analysts, and financial media. This exposure will
raise awareness about the Company and our leading DurAVR™
technology with key stakeholders in the world's largest capital
market. The program will broaden our shareholder base, increasing
trading volumes and liquidity and attracting more institutional
investors. The program will also further support our commercial
strategy in delivering greater value to our shareholders.”
About Anteris Technologies Ltd (ASX: AVR)
Anteris Technologies Ltd (ASX: AVR) is a structural heart
company committed to designing, developing, and commercializing
innovative medical devices. Founded in Australia, with a
significant presence in Minneapolis, USA, a MedTech hub, Anteris is
science driven, with an experienced team of multidisciplinary
professionals delivering transformative solutions to structural
heart disease patients.
The Company’s lead product, DurAVR™ is a transcatheter heart
valve (THV) for the treatment of aortic stenosis. DurAVR™ THV has
been designed in partnership with the world’s leading
interventional cardiologists and cardiac surgeons and is the first
transcatheter aortic valve replacement (TAVR) to use a single piece
of bioengineered tissue. This biomimetic valve is uniquely shaped
to mimic the performance of a healthy, human aortic valve.
DurAVR™ THV is made using ADAPT® tissue, Anteris’ patented,
anti-calcification tissue technology. ADAPT® tissue has been used
clinically for over 10 years and distributed for use in over 50,000
patients worldwide.
The ComASUR™ Delivery System is designed to provide controlled
deployment and accurate placement of the DurAVR™ THV with
balloon-expandable delivery, allowing precise alignment with the
heart’s native commissures to achieve desired valve
positioning.
Anteris Technologies is set to revolutionise the structural
heart market by delivering clinically superior solutions that meet
significant unmet clinical needs.
Authorisation and Additional information
This announcement was authorised by the Board of Directors.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230809932510/en/
Investor Relations (U.S.) Malini Chatterjee, Ph.D.
Managing Director Blueprint Life Science Group +1 917 330 4269
Investor Relations Dejan Toracki Corporate Development
Director Anteris Technologies +61 409 340 641
Website www.anteristech.com Twitter @AnterisTech Facebook
www.facebook.com/AnterisTech LinkedIn
https://www.linkedin.com/company/anteristech
Avaron Mining (TSXV:AVR)
Gráfica de Acción Histórica
De Nov 2024 a Dic 2024
Avaron Mining (TSXV:AVR)
Gráfica de Acción Histórica
De Dic 2023 a Dic 2024